Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Front Immunol. 2024 May 9;15:1387516. doi: 10.3389/fimmu.2024.1387516. eCollection 2024.
It has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. characterizes the co-occurrence, which is one of the common genetic features between these two diseases, indicating shared underlying pathologic mechanisms. Anti-integrin αvβ6 antibody (Ab) is present in sera of UC patients in a highly specific manner. We investigated if there were any associations between anti-integrin αvβ6 Ab and TAK, considering the risk HLA alleles.
A total of 227 Japanese TAK patients were recruited in the current study and their serum samples were subjected to measurement of anti-integrin αvβ6 Ab by ELISA. The clinical information, including the co-occurrence of UC, was collected. The HLA allele carrier status was determined by Luminex or genotype imputation.
The information about the presence of UC was available for 165 patients, among which eight (4.84%) patients had UC. Anti-integrin αvβ6 antibody was identified in 7 out of 8 TAK subjects with UC (87.5%) while only 5 out of 157 (3.18%) TAK subjects without UC had the antibody (OR 121, p=7.46×10). A total of 99 out of 218 (45.4%) patients were carriers. There was no significant association between the presence of anti-integrin αvβ6 Ab and carrier status in those without UC (OR 2.01, 95% CI 0.33-12.4, p = 0.189).
The prevalence of anti-integrin αvβ6 Ab was high in TAK patients with UC, but not in the absence of concomitant UC. The effect of on anti-integrin αvβ6 Ab production would be minimal.
Takayasu 动脉炎(TAK)和溃疡性结肠炎(UC)在同一患者中同时存在的情况已有充分记录。抗整合素 αvβ6 抗体(Ab)在 UC 患者血清中以高度特异性的方式存在,这一特征表明了这两种疾病之间存在共同的遗传特征,提示存在共同的潜在病理机制。我们研究了在考虑风险 HLA 等位基因的情况下,抗整合素 αvβ6 Ab 是否与 TAK 之间存在任何关联。
本研究共招募了 227 名日本 TAK 患者,通过 ELISA 检测其血清样本中的抗整合素 αvβ6 Ab。收集了包括 UC 合并症在内的临床信息。通过 Luminex 或基因分型推断确定 HLA 等位基因携带状态。
在可获得 UC 存在信息的 165 名患者中,有 8 名(4.84%)患者患有 UC。在 8 名患有 UC 的 TAK 患者中有 7 名(87.5%)检测到抗整合素 αvβ6 Ab,而在 157 名没有 UC 的 TAK 患者中仅有 5 名(3.18%)检测到该抗体(OR 121,p=7.46×10)。在 218 名患者中有 99 名(45.4%)是携带者。在没有 UC 的患者中,抗整合素 αvβ6 Ab 的存在与 携带者状态之间没有显著关联(OR 2.01,95%CI 0.33-12.4,p=0.189)。
在患有 UC 的 TAK 患者中,抗整合素 αvβ6 Ab 的患病率较高,但在没有合并 UC 的情况下则不然。 对抗整合素 αvβ6 Ab 产生的影响可能很小。